Evidence of Structural Protein Damage and Membrane Lipid Remodeling in Red Blood Cells from COVID-19 Patients

Tiffany Thomas, Davide Stefanoni, Monika Dzieciatkowska, Aaron Issaian, Travis Nemkov, Ryan C. Hill, Richard O. Francis, Krystaly E. Hudson, Paul W. Buehler, James C. Zimring, Eldad A. Hod, Kirk C. Hansen, Steven L. Spitalnik,*⊥ and Angelo D’Alessandro*,⊥

ABSTRACT: The SARS-CoV-2 beta coronavirus is the etiological driver of COVID-19 disease, which is primarily characterized by shortness of breath, persistent dry cough, and fever. Because they transport oxygen, red blood cells (RBCs) may play a role in the severity of hypoxemia in COVID-19 patients. The present study combines state-of-the-art metabolomics, proteomics, and lipidomics approaches to investigate the impact of COVID-19 on RBCs from 23 healthy subjects and 29 molecularly diagnosed COVID-19 patients. RBCs from COVID-19 patients had increased levels of glycolytic intermediates, accompanied by oxidation and fragmentation of ankyrin, spectrin beta, and the N-terminal cytosolic domain of band 3 (AE1). Significantly altered lipid metabolism was also observed, in particular, short- and medium-chain saturated fatty acids, acyl-carnitines, and sphingolipids. Nonetheless, there were no alterations of clinical hematological parameters, such as RBC count, hematocrit, or mean corpuscular hemoglobin concentration, with only minor increases in mean corpuscular volume. Taken together, these results suggest a significant impact of SARS-CoV-2 infection on RBC structural membrane homeostasis at the protein and lipid levels. Increases in RBC glycolytic metabolites are consistent with a theoretically improved capacity of hemoglobin to off-load oxygen as a function of allosteric modulation by high-energy phosphate compounds, perhaps to counteract COVID-19-induced hypoxia. Conversely, because the N-terminus of AE1 stabilizes deoxyhemoglobin and finely tunes oxygen off-loading and metabolic rewiring toward the hexose monophosphate shunt, RBCs from COVID-19 patients may be less capable of responding to environmental variations in hemoglobin oxygen saturation/oxidant stress when traveling from the lungs to peripheral capillaries and vice versa.

KEYWORDS: SARS-CoV-2, erythrocyte, band 3, AE1, metabolomics, proteomics, lipidomics

INTRODUCTION

A new RNA coronavirus, SARS-CoV-2, is the etiological agent of a severe acute respiratory syndrome (SARS) and associated complications, collectively termed coronavirus disease 2019, or COVID-19.1 Clinically, COVID-19 is characterized by multiple manifestations, including fever, shortness of breath, persistent dry cough, chills, muscle pain, headache, loss of taste or smell, renal dysfunction, and gastrointestinal symptoms. Analogous to other similar coronaviruses,2 SARS-CoV-2 penetrates host cells by interactions between its S (spike) protein and the angiotensin converting enzyme receptor 2 (ACE2),3 the latter is abundantly expressed by lung epithelial cells.4 Alternatively, amino acid residues 111–158 of the beta coronavirus S protein can interact with sialic acids on host-cell gangliosides, an interaction masked by chloroquines, which were proposed for the treatment of COVID-19.5 Of note, proteomics identified angiotensin and ACE2-interacting proteins on the red blood cell (RBC) surface.6 This suggests that RBCs, which cannot support viral replication, may theoretically be invaded by the virus. Indeed, RBCs can be directly or indirectly targeted by pathogens:7 Infecting pathogens may directly penetrate RBCs (e.g., in malaria), directly promote intravascular hemolysis, or indirectly cause hemolysis or accelerate RBC clearance from the bloodstream by splenic and hepatic reticuloendothelial phagocytes.7 Several mechanisms have been proposed to explain these phenomena, including the absorption of immune complexes and complement

Special Issue: Proteomics in Pandemic Disease

Received: August 7, 2020
Published: October 26, 2020
onto RBC surfaces, the development of cross-reacting antibodies, and true autoimmunity with a loss of tolerance secondary to infection. Of note, COVID-19 causes an intense acute-phase response and associated complement system dysregulation.

The absence of organelles in mature RBCs results in tight physiological regulation, including binding and off-loading oxygen, at the post-translational (e.g., phosphorylation, methylation) or metabolic level. High-energy phosphate compounds (e.g., 2,3-diphosphoglycerate (DPG), adenosine triphosphate (ATP)) have clear roles in promoting oxygen off-loading. A recent model proposed that hemoglobin oxygen saturation and deoxygenoglobin binding to the cytosolic N-terminal of band 3 (AE1) function as a sensor of the cell’s redox state and metabolic needs. AE1, the most abundant membrane protein in mature RBCs (∼1 million copies/cell), also participates in the chloride shift (bicarbonate/chloride homeostasis) and as a docking site for several structural proteins that are critical for membrane integrity. In this model, high oxygen saturation favors Fenton chemistry in the iron-rich RBC cytosol. In this setting, the AE1 N-terminal is available to bind and inhibit glycolytic enzyme function (i.e., phosphofructokinase (PFK), aldolase (ALDOA), glyceraldehyde 3-phosphate); inhibiting early glycolysis promotes a metabolic shift toward the pentose phosphate pathway (PPP) to generate reducing equivalents (i.e., NADPH) to cope with oxidant stress. In contrast, at low oxygen saturation, deoxyhemoglobin outcompetes the glycolytic enzymes to bind to the AE1 N-terminus, thereby favoring glycolysis and the generation of ATP and DPG to promote further oxygen release and tissue oxygenation, thus relieving hypoxia. Therefore, because RBCs are critical for oxygen transport and off-loading the severely low oxygen saturations seen in critically ill COVID-19 patients, suggest the importance of determining whether SARS-CoV-2 infection directly or indirectly affects RBC metabolism to influence their gas transport, structural integrity, and circulation in the bloodstream.

COVID-19 presents a wide spectrum of signs and symptoms of varying severity; some patients are asymptomatic, and others require critical care measures, including ventilation, dialysis, and extracorporeal membrane oxygenation. Disease severity and mortality rates are higher in older males and individuals with other comorbidities, including obesity, diabetes, cardiovascular disease, and immunosuppression (e.g., cancer patients undergoing chemo- or radio-therapy and transplant patients). In contrast, women, children, and adolescents tend to be asymptomatic or mildly symptomatic, while still being contagious and contributing to viral transmission. Of note, age and sex significantly affect RBC metabolism in healthy blood donors with respect to energy and redox metabolism. As such, we hypothesized that RBC metabolic differences in COVID-19 patients could contribute to their ability to cope with oxidant stress and hypoxemia and, as such, to the heterogeneity of disease expression. In addition to these considerations, preliminary data were offered by others for peer review, supporting a potential direct structural interaction between SARS-CoV-2 proteins and hemoglobin; if validated, this would provide a direct role for the virus in compromising RBC oxygen transport and delivery.

In light of the above, the present study provides the first comprehensive multimomics analysis of RBCs from noninfected controls and COVID-19 patients, identified by molecular testing of nasopharyngeal swabs.
Figure 1. RBC metabolism and proteome are influenced by COVID-19. Metabolomics and proteomics analyses were performed on RBCs from COVID-19-negative (n = 23) and -positive (n = 29) subjects, as determined by the molecular testing of nasopharyngeal swabs (A). The effects of COVID-19 on RBCs, as gleaned by PLS-DA (B) and hierarchical clustering analysis of the top 50 metabolites (C) and proteins (D) by t test. (E) Volcano plot highlights the significant metabolites and proteins increasing (red) or decreasing (blue) in RBCs from COVID-19 patients as compared with noninfected controls. (F) Pathway analyses were performed on the significant features from the analyses in panels B–E.
Figure 2. COVID-19 significantly affects the RBC glycolysis (A) and the pentose phosphate pathway (PPP) (B), with no significant effect on glutathione homeostasis (C). Metabolomics of RBCs from COVID-19 subjects identified a significant increase in several glycolytic intermediates as compared with controls, including glucose 6-phosphate, fructose bisphosphate, glyceraldehyde 3-phosphate, 2,3-diphosphoglycerate, lactate, and NADH. This phenomenon was at least in part explained by the higher protein levels of PFK, the rate-limiting enzyme of glycolysis, in RBCs from COVID-19 subjects as compared with controls. These subjects also had a significant decreases in the levels of PGM2L1, which catalyzes the synthesis of hexose bisphosphate and thus slows down glycolysis, and GAPDH, a redox-sensitive enzyme. On the contrary, ribose phosphate (isobars), the end product of the PPP, significantly accumulated in RBCs from COVID-19 patients, suggesting a higher degree of oxidant stress in these RBCs; this was confirmed, in part, by the significantly higher levels of GSSG and the lower levels of 5-oxoproline (C). Asterisks indicate significance by t test (* p < 0.05; ** p < 0.01; *** p < 0.001). Groups are color-coded according to the legend in the bottom right corner of the figure.
Pathway analyses were performed with DAVID software and Ingenuity Pathway Analysis. Graphs and statistical analyses were prepared with GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA), GENE E (Broad Institute, Cambridge, MA), and MetaboAnalyst 4.0.

Metabolomics and lipidomics analyses were performed using a Vanquish UHPLC coupled online to a Q Exactive mass spectrometer (ThermoFisher, Bremen, Germany). Samples were analyzed using 5, 15, and 17 min gradients, as described. For targeted quantitative experiments, extraction solutions were supplemented with stable isotope-labeled standards, and endogenous metabolite concentrations were quantified against the areas calculated for heavy isotopologues for each internal standard. Data were analyzed using Maven (Princeton University) and Compound Discoverer 2.1 (ThermoFisher). Graphs and statistical analyses were prepared with GraphPad Prism 8.0, GENE E, and MetaboAnalyst 4.0.

Spearman’s correlations and related p values were calculated with R Studio.

## RESULTS

### COVID-19 Influences RBC Metabolism and Proteome

Metabolomics and proteomics analyses were performed on RBCs from COVID-19-negative (n = 23) and -positive (n = 29)
subjects (Figure 1A; ProteomeXchange ID: PXD022013). With the exception of minor increases in the mean corpuscular volume (MCV), standard hematological parameters did not significantly differ between the two groups, including RBC count, hematocrit (HCT), hemoglobin (Hgb), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and RBC distribution width (RDW; Figure S1). Targeted metabolomics and proteomics analyses (Table S1) identified COVID-19’s effects on RBCs, as gleaned by partial least-squares discriminant analysis (PLS-DA; Figure 1B) and hierarchical clustering analysis of the top 50 significant metabolites (Figure 1C) and proteins (Figure 1D) sorted by t test. A vectorial version of these figures is provided in Figures S2 and S3, respectively. Volcano plot analyses identified significant RBC proteins and metabolites when comparing COVID-19-positive and -negative subjects (Figure 1E); similar analyses were performed using untargeted metabolomics data (Figure S4). Pathway analyses based on these results (Figure 1F) highlighted a significant effect of COVID-19 on protein degradation pathways (including proteasome and ubiquitinylati-
late glycolysis. In contrast, ribose phosphate (isobars), the end product of the PPP, significantly accumulated in RBCs from COVID-19 patients, suggesting greater oxidant stress in these RBCs (Figure 2B). Consistently, RBCs from COVID-19 patients had increased oxidized glutathione (GSGG) but not reduced glutathione (GSH); correspondingly, decreases were seen in 5-oxoproline, a metabolic end product of the RBC γ-glutamyl cycle (Figure 2C). In contrast, RBCs from COVID-19 patients had higher levels of carboxylic acids (α-ketoglutarate, fumarate; Figure 3A), and higher levels of total adenylate pools (ATP, ADP, AMP; Figure 3A). Purine deamination and oxidation products were not significantly increased, with the exception of xanthine; however, significantly lower levels of enzymes involved in purine metabolism were observed in RBCs.

Figure 5. COVID-19 promotes the oxidation and alteration of key structural RBC proteins. Despite no significant changes in the total levels of key structural proteins (e.g., band 3: AE1; spectrin alpha: SPTA1; ankyrin: ANK1) (A), peptidomics analyses showed significant increases and decreases in specific peptides from these proteins. (The heat map in panel B shows the top 50 significant changes by t test.) Further analysis of AE1 identified significant increases in the levels of the peptide spanning amino acid residues 57–74, in contrast with decreased levels of the N-terminal 1–57 peptide (C), as mapped (red) against the PDB 1HYN spanning residues 56–346 of AE2 (gray (D)). In addition, in COVID-19 patients, RBC AE1 was significantly more oxidized (M oxidation + N/Q deamidation) than that in control RBCs (E) in the absence of detectable changes in the levels of peptides beyond residue 75 (F). Similar increases in the levels and oxidation of peptides for SPTA1 (G) and ANK1 (H) were observed, consistent with an effect of COVID-19 on the integrity of RBC structural membrane proteins (I).
from COVID-19 patients, specifically AMP deaminase 3 (AMPD3) and adenylate kinase (ADK; Figure 3A).

No significant alterations were observed for methionine levels, consumption (e.g., to generate S-adenosyl-methionine for isoaspartyl damage repair by PIMT1), or oxidation (i.e., methionine sulfoxide; Figure 3B). However, significantly lower arginine levels were accompanied by (nonsignificant) trends toward increased and decreased levels of ornithine and citrulline, respectively, suggesting potentially increased arginase and decreased nitric oxide synthase activity in RBCs from COVID-19 patients (Figure 3C). In contrast, increased tryptophan oxidation to kynurenine was observed in RBCs from COVID-19 patients in the absence of alterations in tryptophan levels (Figure 3D).

In light of this apparent oxidant stress-related signature, we hypothesized that RBCs from COVID-19 patients may suffer

![](Figure 6. RBC acyl-carnitines (A), saturated fatty acids (B), and oxylipins and resolvins (C) were significantly affected by COVID-19. Asterisks indicate significance by t test (*p < 0.05; **p < 0.01; ***p < 0.001). Groups are color-coded according to the legend in the top left corner of the figure.)
from impaired antioxidant enzyme machinery, perhaps triggered by the degradation of redox enzymes in the context of the ablated de novo protein synthesis capacity in mature RBCs. Although enzyme levels do not necessarily predict enzymatic activity, relative quantities of the main antioxidant enzymes are plotted in Figure 4A, including catalase (CAT), peroxiredoxins (PRDX) 1, 2, and 6, glutathione peroxidases (GPX) 1 and 4, superoxide dismutase (SOD1), γ-glutamyl cysteine ligase (GCLC), glutathione reductase (GSR), glucose 6-phosphate dehydrogenase (G6PD), and biliverdin reductase B (BLVRB). Notably, PRDX1, SOD1, and G6PD were significantly decreased (Figure 4A), suggesting the possible degradation of these enzymes in RBCs from COVID-19 patients. Indeed, these RBCs had higher levels of the components of the proteasome and degradation machinery, such as the ubiquitin-like protein NEDD8, cullin-associated NEDD8-dissociated protein 1 (CAND1), and E3 ubiquitin-protein ligase HUWE1, along with decreases in proteasomal subunit A6 (PSMA6), a part of
the ATP-dependent 25S proteasome (Figure 4B). Taken together, these results suggest increased RBC protein degradation in COVID-19.

COVID-19 Influences Oxidation and Structural Integrity of Key RBC Proteins

Despite no significant changes in the total levels of key structural proteins (e.g., spectrin alpha (SPTA1) and ankyrin (ANK1); Figure 5A), proteomics analysis showed minor increases in AE1 in RBCs from COVID-19 patients. To explain this observation, we hypothesized that increases in AE1 solubility and detection via proteomics approaches could be, at least in part, explained by protein fragmentation, secondary to (oxidant) stress in these patients (Figure S1). To explore the hypothesis, peptidomics analyses were performed, identifying significant increases/decreases in specific peptides from most structural proteins. (The heat map in Figure 5B shows the top 50 significant changes by t test.) Further analysis of AE1-specific peptides from RBCs from COVID-19 patients highlighted significantly increased levels of AE1 peptides spanning amino acid residues 57−74, along with decreased levels from N-terminal residues 1−57 (Figure 5C), as mapped (red) against the PDB 1HYN spanning residues 56−346 of AE1 (gray; Figure 5D). In addition, COVID-19 patient RBC AE1 was significantly more oxidized (determined by the cumulative peak area of peptide hits carrying redox modifications: M oxidation + N/Q deamidation), as compared with that of the controls (Figure 5E), in the absence of detectable changes in peptide levels beyond residue 75 (Figure 5F). Similar increases in the levels and oxidation of peptides from SPTA1 (Figure 5G) and ANK1 (Figure 5H) were observed, consistent with an apparent effect of COVID-19 on the structural integrity of RBC membrane proteins (Figure 5I).

RBCs from COVID-19 Patients Exhibit Significantly Altered Membrane Lipids and Lipid Remodeling Pathways

Lipidomics analyses also suggested alterations in RBC membrane integrity in COVID-19 patients. First, despite comparable RDWs and slightly increased MCVs (Figure S1), membrane integrity in COVID-19 patients. First, despite comparable RDWs and slightly increased MCVs (Figure S1), lipidomics analyses also suggested alterations in RBCs from COVID-19 patients. To explain this observation, we hypothesized that increases in AE1 solubility and detection via proteomics approaches could be, at least in part, explained by protein fragmentation, secondary to (oxidant) stress in these patients (Figure S1). To explore the hypothesis, peptidomics analyses were performed, identifying significant increases/decreases in specific peptides from most structural proteins. (The heat map in Figure 5B shows the top 50 significant changes by t test.) Further analysis of AE1-specific peptides from RBCs from COVID-19 patients highlighted significantly increased levels of AE1 peptides spanning amino acid residues 57−74, along with decreased levels from N-terminal residues 1−57 (Figure 5C), as mapped (red) against the PDB 1HYN spanning residues 56−346 of AE1 (gray; Figure 5D). In addition, COVID-19 patient RBC AE1 was significantly more oxidized (determined by the cumulative peak area of peptide hits carrying redox modifications: M oxidation + N/Q deamidation), as compared with that of the controls (Figure 5E), in the absence of detectable changes in peptide levels beyond residue 75 (Figure 5F). Similar increases in the levels and oxidation of peptides from SPTA1 (Figure 5G) and ANK1 (Figure 5H) were observed, consistent with an apparent effect of COVID-19 on the structural integrity of RBC membrane proteins (Figure 5I).

The present study provides the first multiomics characterization of RBCs from COVID-19 patients. We identified increased glycosylation in RBCs from COVID-19 patients, accompanied by increased oxidation (deamidation of N, oxidation of M, methylation of D,E) of key structural proteins, including the N-terminus of AE1, ANK1, and SPTA1. These changes were accompanied by lower levels of acyl-carnitines, free fatty acids, and most lipids (in particular, SPHs, PAs, and PEs), despite minor increases in the MCV and in the absence of significant changes in the RBC count, HCT, or other clinical hematological parameters. Interestingly, fragmentation/oxidation of the N-terminus of AE1 is expected to disrupt the inhibitory binding of glycolytic enzymes, thereby promoting flux through glycolysis; in turn, hemoglobin oxygen off-loading would be favored via allosteric modulation by RBC DPG (increased in COVID-19) and ATP (trend toward increase) to counteract hypoxia; this interpretation reconciles the metabolomics and peptidomics findings in this study. Conversely, one can speculate that similar to what is observed with (i) genetic variants that favor the splicing of N-terminal amino acids 1−11 of AE1 (i.e., band 3 Neapolis26) or (ii) RBC storage in the blood bank causing fragmentation, proteolysis, or alteration of the oligomeric state of AE1.27,28 RBCs from COVID-19 subjects may have increased susceptibility to oxidant stress-induced lysis and impaired ability to off-load oxygen because their AE1 would be less able to bind (i) inhibit glycolytic enzymes, redverting metabolic fluxes to the PPP to generate reducing equivalents, and (ii) stabilize the tense, deoxygenated state of hemoglobin (Figure 8).29,30 Unfortunately, owing to logistical limitations, we could not directly measure RBC parameters directly related to gas transport physiology, a limitation that we will address in follow-up studies. However, recent studies suggest that RBC hemoglobin oxygen affinity and gas-exchange properties are not compromised, even in severe COVID cases.31,32 As such, this evidence leaves the possibility open that damage to the N-term of band 3 may still compromise the RBC capacity to counteract sudden oxidant stress, such as that arising physiologically while traveling from capillaries to the lungs or iatrogenically, upon pharmacological intervention in these patients. It is not clear whether the alterations of the N-terminus of AE1 is driven by oxidant stress alone or by an enzymatic activity secondary to the infection (e.g., calcium-activated proteases). However, although SARS-CoV-2 encodes cleaving enzymes (e.g., papain-like proteases), comparing our proteomics data with this viral genome did not produce any positive identifications. This suggests that the virus does not penetrate RBCs, or if it does, its protein components are rapidly degraded and not resynthesized owing to the lack of organelles; alternatively, our approach may not be sensitive enough to detect trace viral proteins in the background of ∼250 million hemoglobin molecules per RBC.33 Modification and oxidation of the N-termini of AE1, ANK1, and SPTB were accompanied by altered acyl-carnitines, fatty acids (in particular, saturated short- and medium-chain fatty acids), and lipid metabolism (in particular, SPHs). The latter is
alteration of gas exchange and oxygen availability seems to be confuted by recent reassuring evidence of the lack of transport and delivery of oxygen. However, this interpretation of the data may be incapable of responding to environmental variations in hemoglobin oxygen saturation when traveling from the lungs to peripheral capillaries and, as such, may have a compromised capacity to transport and deliver oxygen. However, this interpretation of the data seems to be confuted by recent reassuring evidence of the lack of alteration of gas exchange and oxygen affinity properties in COVID patients. On the contrary, damage to the N-terminus of AE1 may compromise the RBC capacity to inhibit glycolysis and activate the PPP in response to oxidant stress, making the RBCs from COVID patients more susceptible to oxidant stress. Because the damage to AE1 is irreversible, RBCs circulate for up to 120 days without de novo protein synthesis capacity, and this damage may contribute to explaining some of the long-lasting sequelae of COVID-19.

Figure 8. Model summarizing the proposed findings. Increases in glycolytic metabolites in COVID-19 RBCs are consistent with a theoretically improved capacity of hemoglobin to off-load oxygen as a function of allosteric modulation by high-energy phosphate compounds, perhaps to counteract COVID-19-induced hypoxia. Conversely, because the N-terminus of AE1 stabilizes deoxyhemoglobin and finely tunes oxygen off-loading, RBCs from COVID-19 patients may be incapable of responding to environmental variations in hemoglobin oxygen saturation when traveling from the lungs to peripheral capillaries and, as such, may have a compromised capacity to transport and deliver oxygen. However, this interpretation of the data seems to be confuted by recent reassuring evidence of the lack of alteration of gas exchange and oxygen affinity properties in COVID patients. On the contrary, damage to the N-terminus of AE1 may compromise the RBC capacity to inhibit glycolysis and activate the PPP in response to oxidant stress, making the RBCs from COVID patients more susceptible to oxidant stress. Because the damage to AE1 is irreversible, RBCs circulate for up to 120 days without de novo protein synthesis capacity, and this damage may contribute to explaining some of the long-lasting sequelae of COVID-19.

Interesting because signaling through the N-terminus of AE1 mechanistically cross-regulates with SPHs to promote hemoglobin oxygen off-loading in response to physiological (e.g., high-altitude) or pathological (e.g., sickle cell disease) hypoxia. This signature is consistent with impaired membrane lipid homeostasis, which is not attributable to ATP depletion (not significantly altered in COVID-19 patients). Interestingly, viral infection, including SARS-CoV-2, is associated with altered fatty acid and acyl-carnitine profiles secondary to phospholipase A2 activation. Of note, a redox-sensitive enzyme that is abundant in RBCs, peroxiredoxin 6, also exerts phospholipase A2-like activity. Although PRDX6 levels did not significantly differ between COVID-19 patients and controls, it is interesting that several classes of lysophospholipids were altered in COVID-19 patients. As such, because of the large number of circulating RBCs (~25 trillion in an adult), one may speculate that the increases in serum fatty acids in COVID-19 patients may, at least in part, be due to decreases in the same fatty acids in the erythrocyte compartment. These fatty acids are critical building blocks that sustain the proliferation of replicating viruses, to the extent that they support viral membrane formation prior to decoration with nucleocapsid and spike proteins, as the virus is assembled in target cells (i.e., not RBCs).

Although data regarding disease severity were not available for the subjects in this study, one common manifestation of COVID-19 is a persistent high fever. Interestingly, RBCs exhibit increased vesiculation and altered acyl-carnitine metabolism in response to severe increases in temperature in vivo and in vitro; ATP depletion or activation of the Land cycle were proposed as candidate mechanisms to explain these findings.

We also identified increases in carboxylic acids and pentose phosphate isosbors. In other settings (e.g., the iatrogenic interventions of refrigerated blood storage for clinical purposes or heat shock), RBC accumulation of these metabolites was consistent with the increased oxidant stress-dependent AMPD3 catabolism of high-energy purines. However, with the exception of xanthine, increases in oxidized purines were not observed in COVID-19 patient RBCs, despite higher levels of AMPD3 and lower levels of ADK in these RBCs. In contrast, there were increased steady-state levels of ribose phosphate (and pentose phosphate isosbors), a marker of PPP activation in response to oxidant stress in RBCs, despite decreased levels of G6PD, the rate-limiting enzyme of this pathway. Although relative levels may not reflect the enzymatic activity, one may speculate that the effects of COVID-19 on RBC biology may be exacerbated when the stability and activity of G6PD are modified by natural mutations. Thus G6PD deficiency is the most common human enzymeopathy, affecting ~400 million people worldwide; it also disproportionally affects particular ethnic groups, including African Americans, who are more susceptible to developing severe COVID-19. Because G6PD is also an X-linked gene, it may also partially explain the sex-dependent component of COVID-19 severity, with worse outcomes in male patients. However, despite the inclusion of 14 male and 9 female subjects in the control group and 18 males and 11 females in the COVID-19 group, the present study did not identify major sex-specific signatures for COVID-19 RBCs. Despite the oxidant stress signature observed in COVID-19 RBCs, there were no increases in methionine consumption or oxidation, which are hallmarks of isoaspartyl damage repair of RBC proteins following oxidant insults. Conversely, COVID-19 RBCs exhibited decreased levels of key antioxidant enzymes (PRDX1, SOD1, G6PD) and increased markers of protein degradation (e.g., via the ubiquitin-proteasome system). PRDX2 was a notable exception; increased levels of this protein may be due to increased solubility when released from the membrane, where it binds to the N-terminus of AE1, which was damaged in COVID-19 RBCs. Increased oxidation of structural proteins, along with alterations of lipid compartments, may alter the RBC deformability following SARS-CoV-2 infection. Importantly, the role of RBC morphology and deformability in clot formation and stability are increasingly appreciated. These RBC parameters are tightly regulated by structural protein homeostasis and by the availability of high-energy phosphate compounds required to maintain ion and structural lipid homeostasis (e.g., membrane exposure of phosphatidylserine). As such, the altered RBC structural proteins in COVID-19 may contribute to the thromboembolic and coagulopathic complications seen in some critically ill patients; nonetheless, larger studies will be necessary to test this hypothesis.

Increased levels of kynurenine in RBCs from COVID-19 patients were consistent with prior observations in sera.
Although this is likely due to the equilibrium between kynurenine levels in RBCs and the extracellular environment, it is interesting that increased levels of kynurenine were observed in male, but not female, RBCs following the storage-induced oxidant stress of leukocyte- and platelet-reduced RBC concentrates. 20,49

ABO blood type may be associated with COVID-19 disease severity. In preliminary studies, COVID-19 incidence and severity were increased in Group A subjects, whereas Group O subjects were less affected. 50,51 However, the present study was insufficiently powered to determine the impact of blood type on COVID-19-induced effects on the RBC metabolome and proteome.

Additional limitations of this study pertain to the lack of clinical information on disease severity and stage for the studied COVID-19 patients as well as the lack of longitudinal samples and samples from asymptomatic SARS-CoV-2-infected patients and more appropriately matched uninfected controls (e.g., patients infected by coronaviruses other than SARS-CoV-2), limitations that we will address with the currently ongoing prospective enrollment of patients for future studies at both Columbia University in New York and CU Anschutz in Denver. Similarly, the present study was not sufficiently powered to determine the impact of COVID-19 on RBCs as a function of other biological variables, including subject sex, age, ethnicity, blood type, and habits (e.g., smoking); these are all associated with the RBC’s capacity to cope with oxidant stress and modulate energy metabolism. 20,25-56

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acs.jproteome.0c00606.

Figure S1. No significant effects of COVID-19 were seen on classic clinical hematology parameters, except for increases in the MCV and a nonsignificant trend toward an increase in HCT and Hgb. Figure S2. Vectorial version of the top 50 metabolites by t test in RBCs from COVID-19-positive patients, as compared with controls. Figure S3. Vectorial version of the top 50 proteins by t test in RBCs from COVID-19-positive patients, as compared with controls. Figure S4. Volcano plot of untargeted metabolomics data from the RBC analysis of COVID-19-positive patients, as compared with controls. Figure S5. COVID-19 did not significantly affect levels of mono- and polyunsaturated fatty acids in RBCs (PDF)

Table S1. Omics report (XLSX)

AUTHOR INFORMATION

Corresponding Authors

Angelo D’Alessandro — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States; orcid.org/0000-0002-2258-6490; Phone: 303-724-0096; Email: angelo.dalesandro@ucdenver.edu

Steven L. Spitalnik — Department of Pathology & Cell Biology, Columbia University, New York, New York 10032, United States; Phone: 212-305-2204; Email: ss2479@cumc.columbia.edu

Authors

Tiffany Thomas — Department of Pathology & Cell Biology, Columbia University, New York, New York 10032, United States

Davide Stefanoni — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Monika Dzieciatkowska — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Aaron Issaian — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Travis Nemkov — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Ryan C. Hill — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Richard O. Francis — Department of Pathology & Cell Biology, Columbia University, New York, New York 10032, United States

Kristalyn E. Hudson — Department of Pathology & Cell Biology, Columbia University, New York, New York 10032, United States

Paul W. Buehler — Department of Pathology, University of Maryland, Baltimore, Maryland 21201, United States

James C. Zimring — Department of Pathology, University of Virginia, Charlottesville, Virginia 22903, United States

Eldad A. Hod — Department of Pathology & Cell Biology, Columbia University, New York, New York 10032, United States

Kirk C. Hansen — Department of Biochemistry and Molecular Genetics, University of Colorado Denver — Anschutz Medical Campus, Aurora, Colorado 80045, United States

Complete contact information is available at: https://pubs.acs.org/10.1021/acs.jproteome.0c00606

Author Contributions

‡S.L.S. and A.D. are equally contributing last/senior authors.

Author Contributions

T.T., R.O.F., S.L.S., and E.A.H. designed the study. T.T., R.O.F., and E.A.H. collected and processed the samples. D.S., T.N., M.D., R.C.H., and A.D. performed the omics analyses. A.D. performed the data analysis and prepared the figures and tables. A.D. wrote the first draft of the manuscript, which was significantly revised by S.L.S., T.T., P.W.B., J.C.Z., and K.E.H. and finally approved by all of the authors.

Notes

The authors declare the following competing financial interest(s): Although unrelated to the content of this manuscript, the authors declare that A.D., K.C.H., and T.N. are founders of Omix Technologies, Inc. and Alitis Biosciences LLC. A.D. and S.L.S. are consultants for Hemanext, Inc. A.D. is a consultant for FORMA Therapeutics. S.L.S. is also a consultant for Tioma, Inc. A.D., K.C.H., and J.C.Z. are consultants for Rubius Therapeutics. All of the other authors disclose no conflicts of interest relevant to this study.

The raw data have been uploaded to ProteomeXchange with the identifier no. PXD022013, accessible at the following link: https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=02b4fa2ccaa411988eb8059c6a45544.

ACKNOWLEDGMENTS

This research was supported by funds from the Boettcher Webb-Waring Investigator Award (A.D.), RM1GM131968 (A.D. and K.C.H.) from the National Institute of General and Medical Sciences, and R01HL146442 (A.D.), R01HL149714 (A.D.), and E.A.H. (A.D.), and financial support from Rubius Therapeutics.
Early Step of Coronavirus Replication in Cell Culture.

S.; Ziebuhr, J. Inhibition of Cytosolic Phospholipase A2 by C6-Clomipramine Prevents SARS-CoV-2 Infection. *Journal of Clinical Investigation* 2020, 130 (5), 2270–2285.

Wenham, C.; Smith, J.; Morgan, R. COVID-19: The Gendered Impacts of the Outbreak. *Lancet* 2020, 395 (10277), 846–848.

Matte, A.; Bertoldi, M.; Mohandas, N.; An, X.; Bugatti, A.; Brunati, A. M.; Rusnati, M.; Tibaldi, E.; Siciliano, A.; Turini, F.; Bolondi, S.; De Franceschi, L. Membrane Association of Peroxiredoxin-2 in Red Cells Is Mediated by the N-Terminal Cytoplasmic Domain of Band 3. *Free Radical Biol. Med.* 2015, 85, 27–35.

Byrnes, J. R.; Wolberg, A. S. Red Blood Cells in Thrombosis. *Blood* 2017, 130 (16), 1795–1799.

Alemán, M. M.; Walton, B. L.; Byrnes, J. R.; Wolberg, A. S. Fibrinogen and Red Blood Cells in Venous Thrombosis. *Thromb. Res.* 2014, 133 (1), S38–S50.

Yoshida, T.; Prudent, M.; D’Alessandro, A. Red Blood Cell Storage Lesion: Causes and Potential Clinical Consequences. *Blood Transfus.* 2019, 17 (1), 27–52.

Stefanoni, D.; Shin, H. K. H.; Baek, J. H.; Champagne, D. P.; Nemkov, T.; Thomas, T.; Francis, R. O.; Zimring, J. C.; Yoshida, T.; Reiss, J. A.; Soffing, M.; Perrotta, S.; De Franceschi, L. Membrane Association of Peroxiredoxin-2 in Red Cells Is Mediated by the N-Terminal Cytoplasmic Domain of Band 3. *Free Radical Biol. Med.* 2015, 85, 27–35.

Byrnes, J. R.; Wolberg, A. S. Red Blood Cells in Thrombosis. *Blood* 2017, 130 (16), 1795–1799.

Alemán, M. M.; Walton, B. L.; Byrnes, J. R.; Wolberg, A. S. Fibrinogen and Red Blood Cells in Venous Thrombosis. *Thromb. Res.* 2014, 133 (1), S38–S50.

Yoshida, T.; Prudent, M.; D’Alessandro, A. Red Blood Cell Storage Lesion: Causes and Potential Clinical Consequences. *Blood Transfus.* 2019, 17 (1), 27–52.

Stefanoni, D.; Shin, H. K. H.; Baek, J. H.; Champagne, D. P.; Nemkov, T.; Thomas, T.; Francis, R. O.; Zimring, J. C.; Yoshida, T.; Reiss, J. A.; Soffing, M.; Perrotta, S.; De Franceschi, L. Membrane Association of Peroxiredoxin-2 in Red Cells Is Mediated by the N-Terminal Cytoplasmic Domain of Band 3. *Free Radical Biol. Med.* 2015, 85, 27–35.

Byrnes, J. R.; Wolberg, A. S. Red Blood Cells in Thrombosis. *Blood* 2017, 130 (16), 1795–1799.

Alemán, M. M.; Walton, B. L.; Byrnes, J. R.; Wolberg, A. S. Fibrinogen and Red Blood Cells in Venous Thrombosis. *Thromb. Res.* 2014, 133 (1), S38–S50.

Yoshida, T.; Prudent, M.; D’Alessandro, A. Red Blood Cell Storage Lesion: Causes and Potential Clinical Consequences. *Blood Transfus.* 2019, 17 (1), 27–52.

Stefanoni, D.; Shin, H. K. H.; Baek, J. H.; Champagne, D. P.; Nemkov, T.; Thomas, T.; Francis, R. O.; Zimring, J. C.; Yoshida, T.; Reiss, J. A.; Soffing, M.; Perrotta, S.; De Franceschi, L. Membrane Association of Peroxiredoxin-2 in Red Cells Is Mediated by the N-Terminal Cytoplasmic Domain of Band 3. *Free Radical Biol. Med.* 2015, 85, 27–35.
Stress but Not with Hemolysis in Stored Red Blood Cells from Healthy Blood Donors. Transfusion 2020, 60, 1183.